Improved Response to Immunotherapy with COVID-19 mRNA Vaccines
Introduction Data from a new study presented at the European Society for Medical Oncology (ESMO) meeting and published in Nature…
Melanoma Research
01/13/2026
Improved Response to Immunotherapy with COVID-19 mRNA Vaccines
Introduction Data from a new study presented at the European Society for Medical Oncology (ESMO) meeting and published in Nature…
|
11/07/2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
|
11/02/2025
Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans
Introduction Veterans have been shown to have a higher risk for melanoma compared to the general U.S. population due to…
|
11/02/2025
Overview of Melanoma in Veterans
Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
|
10/22/2025
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
|
|
10/07/2025
You’re Not Out of Options—What To Do After First Line Therapy Fails
Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
|
08/26/2025
Newly Published Trial Data for Melanoma
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
|
08/26/2025
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
|
08/11/2025
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
|
|
07/18/2025
Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar
In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical…
|
Recent Posts
Jan. 13, 2026
The Integrative Care Approach
Jan. 13, 2026
Improved Response to Immunotherapy with COVID-19 mRNA Vaccines
Dec. 09, 2025
One Day at a Time: Caregiving Through Ocular Melanoma
Nov. 24, 2025
A Life Rewritten: Finding Strength in the Face of Melanoma
Nov. 20, 2025